SCHEMBL10099092

SCHEMBL10099092

COc1ccc2c(C)cc(C)nc2c1C

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP1A2 P05177 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 1/20 0.40
NQO2 P16083 1/20 0.39
CRHR1 P34998 3/20 0.39
GPR35 Q9HC97 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8087290 0.84 LMNA (0.47) MAPTKDM4EALDH1A1CYP1A2KMT2A
SCHEMBL10099065 0.83 MAPT (0.56) MAPTKDM4EALDH1A1GAAMAPK1
SCHEMBL10099091 0.83 MAPT (0.56) MAPTKDM4EALDH1A1GAAMAPK1
SCHEMBL10099061 0.80 KDM4E (0.41) MAPTKDM4EALDH1A1CYP1A2KMT2A
SCHEMBL18535287 0.79 KDM4E (0.59) MAPTKDM4EALDH1A1GAACYP1A2
SCHEMBL9890979 0.79 LMNA (0.55) MAPTKDM4EALDH1A1GAAMAPK1
SCHEMBL459073 0.78 KDM4E (0.61) MAPTKDM4EALDH1A1GAAMAPK1
SCHEMBL8271690 0.78 MAPT (0.43) MAPTKDM4EALDH1A1GAACYP1A2
SCHEMBL17921313 0.77 MAPT (0.49) MAPTKDM4EALDH1A1GAAMAPK1
SCHEMBL15256754 0.76 KDM4E (0.59) MAPTKDM4EALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094897-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094897-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HDGF MAPT 4380/4885KDM4E 683/4885ALDH1A1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.